Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The Alexander Shulgin Research Institute (ASRI) is a non-profit research organization dedicated to the study of psychedelic compounds and their therapeutic potential. Based at the historic Shulgin Farm in California, the institute focuses on the synthesis, characterization, and preservation of novel psychoactive substances, particularly phenethylamines and tryptamines. ASRI continues the legacy of Dr. Alexander Sasha Shulgin by maintaining an extensive chemical archive and providing analytical expertise to the scientific community. The institute's work supports the development of new treatments for mental health conditions such as PTSD and depression through the exploration of structure-activity relationships. It serves as a critical resource for researchers seeking to understand the chemistry and pharmacology of serotonergic compounds.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Alexander Shulgin Research Institute.